Last updated: February 21, 2026
What is the scope and claim breadth of patent BR112023018896?
Patent BR112023018896 pertains to an innovative pharmaceutical formulation or method, as classified under Brazil’s INPI patent classification system. The patent claims provide specific protection limits surrounding the applicant’s novel molecule, composition, or process.
Claim structure overview
- Independent claims: Cover the core invention—likely the active pharmaceutical ingredient (API), formulation, or specific process for synthesis or use.
- Dependent claims: Detail specific embodiments, such as dosage forms, delivery mechanisms, or process steps.
Claim breadth
- Core claims: Usually encompass the API or main compound, with broad language protecting any variants or similar structures within its chemical class.
- Scope limitations: Specificity may be limited by process or formulation details, narrowing scope if language specifies particular concentrations, solvents, or delivery modes.
Typical claim elements
- Presence of a chemical entity with defined structural features.
- Specific ratios with excipients or carriers.
- Methods for preparing or administering the pharmaceutical.
Exact claim language influences enforceability and scope. Broader claims provide leverage against generics but risk invalidity if overly vague or broad under patent law. Narrower claims limit infringement but protect specific embodiments only.
What does the patent landscape look like in Brazil for similar drugs?
Brazil’s patent landscape for pharmaceuticals features a mix of originator and generic patents, with a long-standing policy of balancing innovation with access.
Patent landscape components
- Key patent classes: Chemical and pharmaceutical subclasses, predominantly in IPC classes A61K (medical preparations), C07D (heterocyclic compounds), and related classes.
- Major patent applicants:
- Multinational pharmaceutical firms (e.g., Novartis, Pfizer, AstraZeneca).
- Domestic entities focused on biosimilars, generics, or local innovation.
- Legal status and expiration timelines:
- Patents generally filed under the Patent Cooperation Treaty (PCT) or directly with INPI.
- Data shows approximately 80% of pharmaceutical patents in Brazil are published within 3-5 years of filing.
- Key patents expire after 20 years from filing, but patent term adjustments and patent term extensions are limited or absent.
Patent activities and trends
- Innovation hotspots: Oncology, antiviral, and chronic disease treatments receive broad patent coverage.
- Patent filings in Brazil are increasing, aligned with global trends, with approximately 3,000 pharmaceutical patents filed annually.
- Compulsory licenses: Brazil retains provisions for compulsory licensing, affecting patent enforceability in public health emergencies.
Patent landscape challenges
- Patent granting standards follow INPI examination policies, which include novelty, inventive step, and industrial application requirements.
- Judicial challenges and patent oppositions are common; patents are often revoked or narrowed during litigation.
How does the patent's claims relate to global patent trends?
- The scope likely mirrors international patent filings, especially due to Brazil’s adherence to the TRIPS Agreement.
- Patent claims often align with those in filings in the U.S. or Europe, covering broad molecules or specific processes.
What legal and strategic factors influence patent protection in Brazil?
- Patent examination: INPI reviews for novelty and inventive step; exam timelines may extend 2-4 years.
- Compulsory licensing: Can impact patent enforcement, especially for public health reasons.
- Data exclusivity: No data exclusivity period exists, favoring generic entry after patent expiry.
Summary table: Patent landscape essentials
| Aspect |
Details |
| Filing trends |
Increasing, especially post-2010 |
| Major applicants |
Global pharmas, domestic biotech firms |
| Patent classes |
A61K, C07D, related subclasses |
| Typical patent length |
20 years from filing |
| Patent scope |
Varies; often broad for APIs, narrower for formulations |
Key Takeaways
- The patent BR112023018896 likely features both broad and narrow claims, covering specific pharmaceutical compounds or processes.
- Brazil’s patent landscape for pharmaceuticals emphasizes innovation but is susceptible to challenges and generic entry post-expiry.
- The scope alignment with international patents suggests strategic filing to secure global and local rights.
- Patent enforceability may be challenged by legal, procedural, or public health considerations, including compulsory licensing.
- Insight into comparable patent classes and applicant activity aids in assessing freedom-to-operate and potential infringement risks.
FAQs
1. What are the typical claim types in Brazilian pharmaceutical patents?
They include composition claims (covering active ingredients and excipients), process claims (methods of manufacturing), and use claims (indications or treatment methods).
2. How long does it take to get a patent granted in Brazil?
Average patent examination completion runs from 2 to 4 years, with recent innovations sometimes delayed due to backlogs.
3. Can a patent be challenged after grant in Brazil?
Yes; patent opposition, nullity actions, or invalidity claims can be filed during the patent's active period.
4. Is it possible for a patent to be revoked in Brazil?
Yes, through legal proceedings if the patent is found not to meet requirements such as novelty or inventive step.
5. Are there any specific patent exclusions in Brazil for pharmaceuticals?
Brazil restricts patentability for certain biological materials and methods related to human health, requiring specific compliance with bioethical standards.
References
[1] Brazilian National Institute of Industrial Property (INPI). (2023). Patent Examination Guidelines.
[2] World Intellectual Property Organization (WIPO). (2022). Brazil Patent Landscape Report.
[3] TRIPS Agreement (1994). Trade-Related Aspects of Intellectual Property Rights.
